SPRB Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
16.5M
+37.7%
12.0M
+8.0%
11.1M
+34.9%
8.2M
+205.7%
2.7M
R&D
12.2M
+60.6%
7.6M
+84.6%
4.1M
-18.1%
5.0M
+1265.3%
-430000
SG&A
4.3M
-1.4%
4.4M
-36.9%
7.0M
+117.4%
3.2M
+3.1%
3.1M
Operating Income
-16512000
-37.7%
-11987000
-8.0%
-11100000
-34.9%
-8229000
-205.7%
-2692000
EBITDA
-15881000
-35.3%
-11735000
-5.8%
-11095000
-34.9%
-8226000
-206.4%
-2685000
Net Income
-16229000
-32.3%
-12266000
+16.3%
-14646000
-78.3%
-8212000
-297.3%
-2067000
EPS (Basic)
$-6.68
+25.3%
$-8.94
+19.0%
$-11.04
+24.3%
$-14.58
-316.6%
$-3.50
EPS (Diluted)
$-6.68
+25.3%
$-8.94
+19.0%
$-11.04
+24.3%
$-14.58
-316.6%
$-3.50
Shares (Diluted)
2.4M
+77.2%
1.4M
+3.5%
1.3M
+135.5%
563.1K
-4.7%
591.1K
Spruce Biosciences (SPRB) โ€” Financials